Financings in Brief: Centocor Diagnostics
This article was originally published in The Gray Sheet
Centocor Diagnostics: Postpones initial public offering due to adverse market conditions. Parent firm Centocor, Inc. announced plans in October to spin-out shares in its Centocor Diagnostics subsidiary via an IPO of up to $40 mil. in Class A common stock ("The Gray Sheet" Oct. 27, I&W-3). Proceeds from the offering would go towards Centocor Diagnostics' cardiovascular diagnostic program, working capital, R&D and general corporate purposes. Morgan Stanley Dean Witter and Credit Suisse First Boston were to manage the offering...
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”